Filgrastim (Neupogen)

A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Also Known As:

Neupogen; Filgrastim-sndz; G-CSF Recombinant, Human Methionyl; Granix; R-metHuG-CSF; Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor; Tbo-Filgrastim; Topneuter; Zarxio; G CSF Recombinant, Human Methionyl; R metHuG CSF; Recombinant Methionyl Human Granulocyte Colony Stimulating Factor; Tbo Filgrastim

Networked: 1186 relevant articles (125 outcomes, 343 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Crawford, Jeffrey: 14 articles (10/2022 - 01/2002)
2.	Abraham, Ivo: 14 articles (01/2020 - 03/2011)
3.	Aapro, Matti: 13 articles (06/2020 - 03/2011)
4.	MacDonald, Karen: 13 articles (01/2020 - 03/2011)
5.	Krendyukov, Andriy: 12 articles (01/2020 - 01/2017)
6.	Lyman, Gary H: 10 articles (01/2021 - 01/2002)
7.	Gascón, Pere: 10 articles (06/2019 - 03/2011)
8.	Ludwig, Heinz: 8 articles (06/2019 - 03/2011)
9.	Campbell, Kim: 7 articles (01/2021 - 10/2017)
10.	Martino, Massimo: 6 articles (02/2020 - 10/2005)

Related Diseases

1.	Neutropenia 11/01/1994 - "We conclude that R-metHUG-CSF is very effective in shortening the duration of neutropenia in the immediate post-BMT period with lesser BMT morbidity, earlier discharge from hospital and lower cost of BMT. " 08/01/2019 - "Injection Filgrastim was given 300 μg subcutaneous (S/C) or intravenous (I/V) once daily until the neutropenia improved. " 11/01/2019 - "Published randomised controlled trials (RCTs), case reports and reviews analysing the effects of filgrastim on severe neutropenia and its limits were considered. " 05/01/2005 - "The third step was the measurement of the time required for frequently occurring activities in monitoring neutropenia and the administration of filgrastim by a study nurse. " 11/01/2003 - "To study the impact of filgrastim 5 microg/kg given once/day through absolute neutrophil count (ANC) recovery on the duration of grade 4 neutropenia (ANC < 0.5 x 10(3)/mm3) and time to ANC recovery. "
2.	Breast Neoplasms (Breast Cancer) 11/01/1999 - "CP followed by filgrastim is a safe and effective regimen for the mobilization of PBPCs in patients with breast cancer and shows significant activity in patients who failed to mobilize with filgrastim, suggesting a higher mobilization potential." 07/15/2003 - "Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model." 01/01/2002 - "A cost benefit associated with the use of filgrastim in patients with breast cancer has been realised. " 11/01/1999 - "Sixty-four patients with stage II-IV breast cancer received (CP) followed by filgrastim (10 microg/kg/day). " 05/01/1999 - "In this paper, the advantages and disadvantages of these strategies will be discussed, and the results of a recently conducted, randomized, controlled phase 3 clinical trial in breast cancer patients receiving either SCF plus filgrastim or filgrastim alone for PBPC mobilization will be reviewed."
3.	Febrile Neutropenia 10/19/2021 - "Conclusions: Filgrastim was effective and safe in reducing febrile neutropenia and related complications, compared to placebo/no treatment. " 01/01/2009 - "In the two registrational studies of filgrastim, the cumulative incidence of febrile neutropenia (FN) was reduced by about 50% compared with placebo. " 12/01/2022 - "The incidence of febrile neutropenia was 21.6% in the filgrastim cohort and 15% in the filgrastim-aafi cohort (P = 0.179). " 10/19/2021 - "The risk ratio for febrile neutropenia was 0.58, a 42% reduction in favor of filgrastim. " 10/19/2021 - "The risk of febrile neutropenia in filgrastim versus placebo/no treatment was not statistically different. "
4.	Neoplasms (Cancer) 07/01/2000 - "Despite the demonstrated efficacy of filgrastim in primary prophylaxis, its value may be further increased by appropriately selecting patients and better understanding the importance of sustaining dose intensity in specific malignancies. " 11/01/2019 - "Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study." 06/01/1998 - "Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer." 05/01/2023 - "Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary Prophylaxis." 01/06/2023 - "Filgrastim induces the SDF-1/CXCR4 axis on tumor cell growth. "
5.	Infections 07/01/2022 - "However despite filgrastim administration, some study showed FN still occur and cause patient vulnerability to infection. " 01/01/2021 - "Filgrastim administration after CAR T-cell therapy may lead to an increase in severity of CRS without decreasing infection rates." 01/01/2021 - "There was no difference in the incidence and severity of infection based on filgrastim use (P = .274, P = .138). " 12/01/2015 - "The number of documented infections was significantly less in the TBO-filgrastim group. " 03/01/2014 - "The primary outcomes were time from initiation of filgrastim to recovery of stable neutrophil count of >500 cells/µL and a composite clinical outcome of infection or death assessed for the first course post-randomization. "

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	pegfilgrastim (Neulasta)
3.	Filgrastim (Neupogen)
4.	Biosimilar Pharmaceuticals
5.	Doxorubicin (Adriamycin)
6.	Cyclophosphamide (Cytoxan)
7.	Anti-Bacterial Agents (Antibiotics)
8.	Lenograstim
9.	Epirubicin (Ellence)
10.	Vincristine (Oncovin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Stem Cell Transplantation
4.	Transplantation
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)